The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of polyphenon E (P) in addition to erlotinib (E) in advanced non-small cell lung cancer (NSCLC).
H. B. Illum
No relevant relationships to disclose
S. H. R. Jafri
No relevant relationships to disclose
J. Mclarty
No relevant relationships to disclose
G. M. Mills
No relevant relationships to disclose
J. Dowell
No relevant relationships to disclose
A. Sharma
No relevant relationships to disclose
D. H. Wang
No relevant relationships to disclose
M. Lowery Nordberg
No relevant relationships to disclose
J. Cardelli
No relevant relationships to disclose